This summary covers recent health news, including stable pig prices in Germany, investor focus on AstraZeneca's China probe, ...

Medscape Medical News, February 06, 2025 Argentina to Ban Hormone Therapy ... Medscape Medical News, February 05, 2025 Novo Nordisk to Seek Regulatory Approval for CagriSema Obesity Drug Early ...

The higher he climbs, the less he thinks about daily life, says Novo Nordisk’s Cem Ozenc. There’s no time when the mental and ...

Additionally, the spread of bird flu, Novo Nordisk's drug defenses, Eli Lilly sales strategies, and Argentina's transgender policy are discussed. This image is AI-generated and does not depict any ...

Fique por dentro das últimas notícias sobre a Bolsa, Mercado Financeiro e dinheiro. Confira também dicas de investimentos e ...

O Fundo Monetário Internacional (FMI) indicou hoje que as negociações com o Governo da Argentina para um novo programa de assistência prosseguem "de forma construtiva e frequente".

Novo Nordisk A/S Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission ...

Good day, and thank you for standing by. Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes and weight loss medicines, including Wegovy and ...

Novo Nordisk reported $40.5 billion in sales for 2024, surpassing Wall Street’s expectations. Its success was driven by its two GLP-1 drugs, Ozempic and Wegovy. The company is in a race with ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...